ITEM 7.01.

REGULATION FD DISCLOSURE.

On December 7, 2005, Constellation Brands, Inc. (“Constellation”) issued a press release, attached hereto as Exhibit 99.1, in which it provided information regarding the time and manner in which shareholders of Vincor International Inc. (“Vincor”) may tender to Constellation’s previously announced enhanced offer to acquire all of the outstanding common shares (and associated Poison Pill Rights) of Vincor.    

This Current Report on Form 8-K, including the exhibit hereto, is being furnished in lieu of a tender offer filing, since Vincor International Inc. does not have a class of equity securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended.

References to Constellation's website in the press release attached as Exhibit 99.1 do not incorporate by reference the information on such website into this Current Report on Form 8-K and Constellation disclaims any such incorporation by reference. The information included in this Current Report on Form 8-K and the press release attached as Exhibit 99.1, are incorporated by reference into this Item 7.01 in satisfaction of the public disclosure requirements of Regulation FD. This information is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934 or the Securities Act of 1933 only if and to the extent such subsequent filing specifically references the information incorporated by reference herein.